Mark A. Hillman
Hillman Value Fund
Mark A. Hillman GlaxoSmithKline PLC ADR stake
total: 75
Hillman Value Fund GSK trades
- Total transactions:
- 9
- New positions:
- 1
- Added:
- 2
- Reduced:
- 6
- Held since:
- 2021 Q1
- Held for:
- 21 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q1 report, Mark A. Hillman holds 41,000 GlaxoSmithKline PLC ADR (GSK) shares with a market value of roughly $2.26M accounting for 2.73% of the overall portfolio. To date, the estimated cost basis is nearly $39.48 for "buy" trades and estimated average "sell" price is $40.99. Hillman Value Fund first purchased GSK in 2021 Q1, initially acquiring 128,000 shares. Since the initial investment in GlaxoSmithKline PLC ADR (GSK), Hillman Value Fund has made 8 more transactions.
When did Mark A. Hillman buy GlaxoSmithKline PLC ADR (GSK)?
Mark A. Hillman first invested in GlaxoSmithKline PLC ADR (GSK) in 2021 Q1 at the reported quarter-end price of $44.61 per share.
What's the cost basis of Hillman Value Fund's GSK stake?
The estimated cost basis for GlaxoSmithKline PLC ADR (GSK) stake is around $39.48 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $39.48
- Weighted AVG sell price:
- $40.99
Mark A. Hillman's historical trades in GlaxoSmithKline PLC ADR
9 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
2.73%
|
41,000
|
$55.19
|
$2,262,790
|
-18.16% (-9,100)
|
-0.54%
|
|
2025 Q4
|
2.62%
|
50,100
|
$49.04
|
$2,456,904
|
-27.71% (-19,200)
|
-0.9%
|
|
2025 Q3
|
2.85%
|
69,300
|
$43.16
|
$2,990,988
|
-12.72% (-10,100)
|
-0.37%
|
|
2025 Q2
|
2.57%
|
79,400
|
$38.40
|
$3,048,960
|
-14.16% (-13,100)
|
-0.35%
|
|
2025 Q1
|
2.52%
|
92,500
|
$38.74
|
$3,583,450
|
-46.13% (-79,200)
|
-1.45%
|
|
2024 Q4
|
2.75%
|
171,700
|
$33.82
|
$5,806,894
|
+27.09% (+36,600)
|
+0.59%
|
|
2024 Q2
|
2.29%
|
135,100
|
$38.50
|
$5,201,350
|
-21.85% (-37,765)
|
-0.6%
|
|
2022 Q3
|
2.83%
|
172,865
|
$29.43
|
$5,087,417
|
+35.05% (+44,865)
|
+0.73%
|
|
2021 Q1
|
3.30%
|
128,000
|
$44.61
|
$5,710,400
|
new
|
+3.3%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.